Molecular evidence for increased antitumor activity of gemcitabine in combination with a cyclin-dependent kinase inhibitor, P276-00 in pancreatic cancers

Journal of Translational Medicine

Volumn 10, Issue 1, 2012, Pages

  Rathos, Maggie J ^a   Joshi, Kavita ^a   Khanwalkar, Harshal ^a   Manohar, Sonal M ^a   Joshi, Kalpana S ^a  

^a Piramal Enterprises Limited   (India)

Author keywords

Cdk inhibitor; Combination studies; Gemcitabine; P276 00; Pancreatic cancer

Indexed keywords

CYCLIN D1; CYCLIN DEPENDENT KINASE 4; CYCLIN DEPENDENT KINASE INHIBITOR; CYCLOOXYGENASE 2; GEMCITABINE; P27600; PROTEIN BCL 2; PROTEIN BNIP3; PROTEIN P8; SURVIVIN; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CANCER INHIBITION; CELL CYCLE; CELL CYCLE ARREST; CELL CYCLE PROGRESSION; CELL PROLIFERATION; CONTROLLED STUDY; CYTOTOXICITY; DOSE RESPONSE; DOWN REGULATION; DRUG EFFICACY; FLOW CYTOMETRY; HUMAN; HUMAN CELL; MALE; MOUSE; MULTIPLE CYCLE TREATMENT; NONHUMAN; PANCREAS CANCER; PHASE 2 CLINICAL TRIAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TUMOR VOLUME; WESTERN BLOTTING;

BASE SEQUENCE; CELL LINE, TUMOR; CYCLIN-DEPENDENT KINASES; DEOXYCYTIDINE; DNA PRIMERS; FLAVONES; HUMANS; PANCREATIC NEOPLASMS; PROTEIN KINASE INHIBITORS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION;

EID: 84864568987     PISSN: None     EISSN: 14795876     Source Type: Journal    
DOI: 10.1186/1479-5876-10-161     Document Type: Article

References (29)

1. Hidalgo M. Pancreatic cancer. N Engl J Med 2010, 362:1605-1617. 10.1056/NEJMra0901557, 20427809.
2. Parikh AA, Lowy AM. Pancreatic cancer, can we screen? How should we stage?. Curr Gastroenteral Rep 1999, 1:166-174.
3. Haller DG. New perspectives in the management of pancreas cancer. Semin Oncol 2003, 30:3-10.
4. Burris HA, Moore MJ, Anderson J, et al. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol 1997, 15:2403-2413.
5. Biology of pancreatic cancer. Gastrointestinal cancers 2003, 519-528. W. B. Saunders Co, Rustgi AK, Crawford J.
6. Kaino M. Alterations in the tumor suppressor genes p53, RB, p16/MTS1, and p15/MTS2 in human pancreatic cancer and hepatoma cell lines. J Gastroenterol 1997, 32:40-46. 10.1007/BF01213295, 9058294.
7. Cowgill SM, Muscarella P. The genetics of pancreatic cancer. Am J Surg 2003, 186:279-286. 10.1016/S0002-9610(03)00226-5, 12946833.
8. Collins I, Garrett MD. Targeting the cell division cycle in cancer: CDK and cell cycle checkpoint kinase inhibitors. Curr Opin Pharmacol 2005, 5:366-373. 10.1016/j.coph.2005.04.009, 15964238.
9. Hanahan D, Weinberg RA. The hallmarks of cancer. Cell 2000, 100:57-70. 10.1016/S0092-8674(00)81683-9, 10647931.
10. Vermeulen K, Van Bockstaele DR, Berneman ZN. The cell cycle: a review of regulation, deregulation and therapeutic targets in cancer. Cell Prolif 2003, 36:131-149. 10.1046/j.1365-2184.2003.00266.x, 12814430.
11. Schwartz GK, Shah MA. Targeting the cell cycle: a new approach to cancer therapy. J Clin Oncol 2005, 23:9408-9421. 10.1200/JCO.2005.01.5594, 16361640.
12. Shapiro GI. Cyclin-dependent kinase pathways as targets for cancer treatment. J Clin Oncol 2006, 24:1770-1783. 10.1200/JCO.2005.03.7689, 16603719.
13. Joshi KS, Rathos MJ, Joshi RD, et al. In vitro antitumor properties of a novel cyclin-dependent kinase inhibitor, P276-00. Mol Cancer Ther 2007, 6:918-925. 10.1158/1535-7163.MCT-06-0613, 17363486.
14. Joshi KS, Rathos MJ, Mahajan P, et al. P276-00, a novel cyclin-dependent inhibitor induces G1-G2 arrest, shows antitumor activity on cisplatin-resistant cells and significant in vivo efficacy in tumor models. Mol Cancer Ther 2007, 6:926-934. 10.1158/1535-7163.MCT-06-0614, 17363487.
15. Dengler WA, Schulte J, Berger DP, Mertelsmann R, Fiebig HH. Development of a propidium fluorescence assay for proliferation and cytotoxicity assays. Anticancer Drugs 1995, 6:522-532. 10.1097/00001813-199508000-00005, 7579556.
16. Chau YJ, Cunningham D. Adjuvant treatment for respectable pancreatic cancer. J Clin Oncol 2005, 23:4532-4537. 10.1200/JCO.2005.17.954, 16002844.
17. Chou T-C. Theoretical basis, experimental design, and computerized simulation of synergism and antagonism in drug combination studies. Pharmacol Rev 2006, 58:621-681. 10.1124/pr.58.3.10, 16968952.
18. Berlin JD, Rothenberg ML. Chemotherapeutic advances in pancreatic cancer. Curr Oncol Rep 2003, 5:219-226. 10.1007/s11912-003-0113-8, 12667419.
19. Diaz-Rubio E. New chemotherapeutic advances in pancreatic, colorectal, and gastric cancers. Oncologist 2004, 9:282-294. 10.1634/theoncologist.9-3-282, 15169983.
20. Arends JJ, Sleeboom HP, Leys MB, et al. A phase II study of raltitrexed and gemcitabine in patients with advanced pancreatic carcinoma. Br J Cancer 2005, 92:445-448. 2362068, 15668704.
21. Bold RJ, Virudachalam S, McConkey DJ. BCL2 expression correlates with metastatic potential in pancreatic cancer cell lines. Cancer 2001, 92(5):1122-1129. 10.1002/1097-0142(20010901)92:5<1122::AID-CNCR1429>3.0.CO;2-H, 11571724.
22. Nakano Y, Tanno S, Koizumi K, Nishikawa T, Nakamura K, Minoguchi M, Izawa T, Mizukami Y, Okumura T, Kohgo Y. Gemcitabine chemoresistance and molecular markers associated with gemcitabine transport and metabolism in human pancreatic cancer cells. Br J Cancer 2007, 96:457-463. 10.1038/sj.bjc.6603559, 2360025, 17224927.
23. Yip Schneider MT, Barnard DS, Billings SD, et al. Cyclooxygenase-2 expression in human pancreatic adenocarcinomas. Carcinogenesis 2000, 21:139-146. 10.1093/carcin/21.2.139, 10657949.
24. Kokawa A, Kondo H, Gotoda T, Ono H, et al. Increased expression of cyclooxygenase-2 in human pancreatic neoplasms and potential for chemoprevention by cycloxgenase inhibitors. Cancer 2001, 91:333-338. 10.1002/1097-0142(20010115)91:2<333::AID-CNCR1006>3.0.CO;2-N, 11180079.
25. Aoki T, Nagakawa Y, Tsuchida A, et al. Expression of cyclooxygenase-2 and vascular endothelial growth factor in pancreatic tumours. Oncol Rep 2002, 9:761-765.
26. Okami J, Yamamoto H, Fujiwara Y, et al. Overexpression of cyclooxygenase-2 in carcinoma of the pancreas. Clin Cancer Res 1999, 5:2018-2024.
27. Giroux V, Malicet C, Barthet M, et al. p8 Is a NewTarget of Gemcitabine in Pancreatic Cancer Cells. Clin Cancer Res 2006, 235:235-241.
28. Akada M, Crnogorac-Jurcevic T, Lattimore S, et al. Intrinsic chemoresistance to gemcitabine is associated with decreased expression of BNIP3 in pancreatic cancer. Clin Cancer Res 2005, 11:3094-3101. 10.1158/1078-0432.CCR-04-1785, 15837765.
29. Okami J, Simeone DM, Logsdon CD. Silencing of the Hypoxia-Inducible Cell Death Protein BNIP3 in pancreatic cancer. Cancer Res 2004, 64:5338-5346. 10.1158/0008-5472.CAN-04-0089, 15289340.